Norwalk, Connecticut — October 9, 2025 — Leads & Copy — Lifespan Vision Ventures announces that its portfolio company, Algen Biotechnologies, has entered into a multi-target research collaboration with AstraZeneca to advance AI-powered drug discovery in immunology.
The partnership will combine Algen’s functional genomics and machine learning platform with AstraZeneca’s expertise and R&D capabilities. The companies aim to identify and validate novel therapeutic targets for immune-mediated and inflammatory diseases, accelerating the discovery of next-generation medicines.
Lifespan Vision Ventures Principal Harry Robb said the team has built a differentiated platform that integrates CRISPR-based functional screening with advanced AI analytics to uncover disease-relevant biology at scale. He added that this collaboration with AstraZeneca underscores the strength of Algen’s technology and its potential to transform drug discovery.
Lifespan Vision Ventures is an early investor supporting Algen Biotechnologies in its mission to advance therapies that improve patient outcomes in age-related diseases and extend healthspan.
Algen Biotechnologies, founded by Chun-Hao Huang and Christine Du, is headquartered in San Francisco, CA.
Contact: info@lifespanvision.com
Source: LifeSpan Vision Ventures
